跳至主要内容
临床试验/NCT02000154
NCT02000154已完成1 期

Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome - Extension Study

SymBio Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
1
试验地点
2
主要终点
Adverse Events

研究概览

简要总结

This is an extension study study to investigate long term safety of SyB L-1101 when administered intravenously every 4 weeks to the patients who have completed 8 cycles in the study 2011005 whose purpose is to investigate tolerability of SyB L-1101 when administered intravenously in patients with recurrent/relapsed or refractory myelodysplastic syndrome. Antitumor effects will also be investigated in this study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must satisfy the following conditions listed below.
  • Patients enrolled in the study 2011005 of SyB L-1101 in Patients With Myelodysplastic Syndrome.
  • Patients who was not judged as disease progression* nor progressive disease/relapsed** at the end of the cycle 8 in the study
  • * hematologic remission according to IWG 2006 criteria ** hematologic improvement according to IWG 2006 criteria
  • Patients who met the continuation criteria*** after Cycle 8 week 2 (Day 15±3) in the study 2011005.***defined in the study 2011005 protocol
  • Patients who can be expected to survive at least three months or longer.
  • Patients who have score of 0 to 2 in Eastern Cooperative Oncology Grou (ECOG) Performance Status (P.S.).
  • Patients with adequate function in major organs (heart, lungs, liver, kidneys, etc.).
  • Aspartate aminotransferase (AST): no more than 3.0 times the upper boundary of the reference range at each institution
  • Alanine aminotransferase (ALT): no more than 3.0 times the upper boundary of the reference range at each institution
  • Total bilirubin: no more than 1.5 times the upper boundary of the reference range at each institution
  • Serum creatinine: no more than 1.5 times the upper boundary of the reference range at each institution
  • ECG: no abnormal findings requiring treatment
  • Echocardiography: no abnormal findings requiring treatment
  • Patients who personally signed an informed consent document for participation in this study.

排除标准

  • Patients who satisfy any of the following conditions will not be enrolled in the study.
  • Patients with anemia (haemolytic anaemia, gastrointestinal haemorrhage, etc.) caused by factors other than MDS.
  • Patients with obvious infectious diseases (including viral infections).
  • Patients with serious complications (liver failure, renal failure, etc.).
  • Patients with a complication of serious heart disease (myocardial infarction, ischemic heart disease, etc.)
  • Patients with a serious gastrointestinal condition (severe or significant nausea/vomiting, diarrhea, etc.)
  • Patients with serious bleeding tendencies (disseminated intravascular coagulation (DIC), internal hemorrhage, etc.).
  • Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of <130 milliequivalent/L).
  • Patients with an addiction to a legal or illegal drug, or with alcohol dependency.
  • Patients who are nursing, pregnant or may become pregnant.
  • Patients who have not consented to the following contraceptive measures. Patients will avoid sexual intercourse with sexual partners or should use the following contraceptive methods in these time periods: for male patients during the administration period of the trial and for six months after the end of administration; female patients during the administration period of the trial, and until a second menstrual period is confirmed after the end of administration (or in the case of female patients with no menstrual period, for two months after the end of administration). (1) Male patients:The patient will always use a condom. For effective contraception, it is recommended that the female partner also use the contraceptive methods for female patients. (2) Female patients: Female patients who may become pregnant should use one or more types of the following contraceptive methods. In addition, the male partner will always use a condom.
  • Oral contraceptive (birth control pills)
  • Intrauterine device (IUD)
  • Tubal ligation
  • Other patients judged to be unsuitable by an investigator or sub-investigator.

研究组 & 干预措施

SyB L-1101

Experimental

干预措施: SyB L-1101 (Drug)

结局指标

主要结局

Adverse Events

时间窗: Up to 20 weeks

Total number affected by any adverse events (details are presented in adverse event section)

次要结局

  • Disease Response Assessment(Up to 20 weeks)
  • Serious Adverse Events(Up to 20 weeks)
  • Hematologic Improvement(Up to 20 weeks)
  • Cytogenetic Response(Up to 20 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Long Term Safety Study of SyB L-1101 in Patients... | 临床试验